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Abstract The tissue-type plasminogen activator (t-PA) and
plasminogen activator inhibitor type 2 (PAI-2) genes are
differentially regulated by 12-phorbol 13-myristate acetate
(PMA) in HT-1080 fibrosarcoma cells. PMA transcriptionally
down-regulates the t-PA gene in HT-1080 cells, while the PAI-2
gene is simultaneously induced by this agonist. The t-PA and
PAI-2 gene promoters harbour a cAMP-response element (CRE)
which influences the expression of both genes. We have compared
the binding activity of nuclear factors that recognise these CRE
sites. We show that CREB (CRE binding protein) recognises
each CRE and that the degree of constitutive Ser119-phosphory-
lated t-PA CRE-bound CREB was greater than for PAI-2 CRE
bound CREB. Stable transfection of HT-1080 cells with a
plasmid containing a CREB that could not be phosphorylated on
Ser119 (pCI-CREBala119) did not influence PMA-mediated
suppression of t-PA mRNA, but markedly impaired PMA-
mediated induction of PAI-2 mRNA. Our results demonstrate
that the Ser119 residue of CREB plays a crucial role in PMA-
mediated induction of PAI-2 gene expression, whereas PMA-
mediated suppression of t-PA in HT-1080 cells requires a
different process. ß 2000 Federation of European Biochemical
Societies. Published by Elsevier Science B.V. All rights re-
served.
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1. Introduction
Extracellular proteolysis mediated by the plasminogen acti-
vating system is crucial for many biological phenomena. It is
widely accepted that the primary role of this system concerns
its ¢brinolytic function, particularly in the maintenance of
vascular patency. However, this proteolytic cascade is also
implicated in other processes, including embryonic develop-
ment, cell movement, metastatic spread of some malignancies
[1] and, more recently, in synaptic plasticity [2,3] and neuro-
degeneration [4]. Given the broad action of the plasminogen
activating system, it is not surprising that the genes encoding
its individual protein components are highly regulated by var-
ious agents, including cytokines, hormones and excitotoxins.
In some cases, the regulation pattern of some members of this
system is cell-type dependent. For example, the tumour pro-
moter 12-phorbol 13-myristate acetate (PMA) induces tissue-
type plasminogen activator (t-PA) gene expression in HeLa
cells and in endothelial cells, yet suppresses t-PA expression
in HT-1080 ¢brosarcoma cells [5^7]. Interestingly, a cis-acting
DNA element related to the cAMP responsive element (CRE)
in the t-PA gene promoter (tPACRE; TGACATCA) is re-
ported to play a role in PMA-modulated induction of t-PA
expression in endothelial cells and in HeLa cells [5,8]. In
HT-1080 cells, constitutive t-PA gene expression is relatively
high and mutation of the tPACRE substantially reduces basal
t-PA promoter activity. However, it remains to be determined
whether this element is also required to convey PMA-medi-
ated suppression. Taken together, these observations led to
the idea that the assembly of transcription factors associating
with the tPACRE orchestrates the cell-speci¢c response of the
t-PA gene to PMA [9]. The plasminogen activator inhibitor
type 2 (PAI-2) gene, on the other hand, is not at all expressed
or regulated in HeLa cells, but is strongly induced by PMA in
HT-1080 cells and in endothelial cells. DNA mutagenesis and
transfection assays of the PAI-2 gene promoter have also
revealed that a CRE-like element located at position 390 to
380 (PAI-2 CRE; TGACCTCA), is an absolute requirement
for basal and PMA inducible expression of the PAI-2 gene at
least in transfected HT-1080 cells [10]. The cell-speci¢c regu-
lation of the t-PA and PAI-2 genes and a common require-
ment for a functional CRE in their respective gene promoters
lends additional circumstantial support that the factors inter-
acting with the t-PA and PAI-2 CRE sites in£uence the tissue-
speci¢c expression pattern of these two genes.
CRE motifs provide speci¢c binding sites for transcription
factors that are members of the CREB/ATF or the fos/jun
families [11]. Although PAI-2 CRE binding factors have yet
to be identi¢ed, tPACRE binding proteins in the nuclei of
primary human umbilical vein endothelial cells have been
identi¢ed as CREB, CREM, ATF-2 and c-jun [8]. Interest-
ingly, CREB was also found be a prominent tPACRE binding
protein in nuclear extracts prepared from HT-1080 cells [9].
The opposite regulation of the t-PA gene by PMA in endo-
thelial cells and in HT-1080 cells raised the possibility that
CREB may play a dual role in the regulation of t-PA and
contribute to the positive and negative e¡ects of PMA on the
t-PA gene in these cell types.
The transcriptional e¡ects of CREB depend to some extent
on its association with other factors in a process that requires
phosphorylation of a serine residue located at position 119
(Ser119) [11]. Although CREB is implicated in the regulation
of t-PA gene regulation, the phosphorylation status of CREB
associating with the tPACRE in any of the cell systems
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studied to date and the signi¢cance of this remains to be
determined.
In this study, we have assessed the role of CREB in the
regulation of the t-PA and PAI-2 genes in HT-1080 cells. Our
results demonstrate that the PAI-2 CRE site provides a bind-
ing site for various members of the CREB/ATF family of
proteins, including c-jun and CREB. Importantly, we show
that the degree of Ser119-phosphorylated CREB bound to
both tPACRE and PAI-2 CRE sites di¡ers. Using a dominant
negative approach to explore the role of CREB in the regu-
lation of the t-PA and PAI-2 genes, our data indicate that the
Ser119 residue in the CREB protein is required to convey
PMA-mediated induction of PAI-2 expression in HT-1080
cells yet has little, if any, in£uence on PMA-mediated suppres-
sion of the t-PA gene. Hence, this study indicates for the ¢rst
time the functional role of CREB in PMA-mediated induction
of PAI-2 gene expression.
2. Materials and methods
2.1. Cell culture
Human HT-1080 ¢brosarcoma cells were maintained in Dulbecco’s
modi¢ed Eagle’s medium as previously described [9]. Where indicated,
cells were treated for up to 48 h with 25 nM PMA (Sigma).
2.2. Northern blot procedure
Total RNA was isolated from cells [12] and 10 Wg of total RNA
was loaded to each lane and electrophoresed through a 1% agarose gel
containing 20% formaldehyde before being transferred to Hybond-N
membrane (Amersham, Australia). Filters were hybridised overnight
at 42‡C in 50% formamide hybridisation bu¡er as previously de-
scribed [13]. 32P-Labeling of DNA was performed by the random
priming procedure using the Prima-gene labeling kit (Promega, Aus-
tralia). cDNA inserts used for this study included the BglII fragment
of the plasmid p114B containing the t-PA cDNA [14], the EcoR1
fragment of plasmid pJ7 containing the 1.9-kb cDNA insert of PAI-
2 [15] and the BglII insert of type 1 collagenase (1.8 kb, kindly pro-
vided by Dr Peter Angel, Germany). Plasmids harbouring the full-
length mouse L-actin cDNA were denatured at 100‡C, and directly
labeled. After hybridisation, the membranes were washed by standard
techniques and exposed to Kodak BioMax ¢lm (Eastman Kodak,
Rochester, NY, USA) at 370‡C with an intensifying screen.
2.3. Preparation and labeling of oligonucleotides
The labeling of gel puri¢ed oligomers (100 ng) was performed using
T4 polynucleotide kinase and 32P Q-ATP [9]. Annealing was performed
by adding a four-fold molar excess of the complementary strand to
the kinase-treated, heat-inactivated mixture [9].
2.4. Electrophoretic mobility shift assay (EMSA) and supershift
procedure
Four Wg of nuclear proteins extracted from HT-1080 cells, were
prepared in 4 Wl of Osborne bu¡er D [16] and EMSAs were performed
[9]. The sequences of the labeled oligomers are provided in the ¢gure
legends.
Commercial monoclonal or polyclonal antibodies against ATF-1,
ATF-2, CREB, CREM, c-fos, c-jun and jun-D speci¢cally designed for
supershift experiments were obtained from Santa Cruz Inc. (USA).
Commercial antibody against Ser119-phosphorylated CREB was ob-
tained from Signal Transduction laboratories (USA). Supershifting
was performed using the same procedure as for standard EMSA ex-
cept that speci¢c antibody (1^3 Wg total) was added to the nuclear
extracts for 1 h after the addition of the labeled oligomers [9].
2.5. Mutagenesis
2.5.1. Generation of a dominant negative CREB. Site-directed mu-
tagenesis of the human CREB cDNA sequence was performed using
the Transformer DNA kit (Clontech, USA), following the manufac-
turers instructions. The mutagenic primer (5P-AGGAGGCCTGCC-
TACAGGAAA-3P) was designed to replace the codon TCC (a serine
residue) at position 119 with GCC (underlined in primer sequence),
thereby creating an alanine residue at this position (CREBala119). The
human CREB cDNA (kindly provided by Dr Gerard Waeber, Lau-
sanne, Switzerland) was obtained as an EcoRI fragment in plasmid
pGEM-7Zf(+).
The selection primer (5P-GAAATCGATCATATGGGATCCGGA-
GAGC-3P) was designed to substitute the HindIII site in plasmid
pGEM 7Zf(+) with NdeI. The wild-type and mutated CREB cDNAs
were removed from the pGEM-7Zf(+) plasmid by EcoRI digestion
and inserted into the EcoRI site of pCI-neo (Promega) following stan-
dard techniques, creating plasmids pCI-CREBwt and pCI-CREBala119,
respectively. The orientation of the inserted CREB cDNAs was con-
¢rmed by sequencing.
2.6. Transfection studies
Stable transfection of pCI-neo, pCI-CREBwt or pCI-CREBala119
expression plasmids into HT-1080 cells was performed by the Qiagen
Superfect reagent (Qiagen) following the manufacturer’s instructions.
Stably transfected cells were selected on the basis of resistance to
G418 (600 Wg/ml).
Fig. 1. Identi¢cation and comparison of tPACRE and PAI-2 CRE
binding proteins in HT-1080 cells. A supershift experiment was per-
formed to identify the tPACRE and PAI-2 CRE binding proteins in
HT-1080 cells. Nuclear extracts prepared from non-treated HT-1080
cells were incubated with a labeled double-stranded 22-bp oligonu-
cleotide harbouring the region between positions 3119 and 398 in
the t-PA promoter (5P-ATTCAATGACATCACGGCTGTG-3P)
which contains tPACRE (underlined) (top panel). An identical ex-
periment was performed using a double-stranded 22-bp oligomer ho-
mologous to the region between positions 3196 and 3175 of the
PAI-2 gene promoter (5P-TTCAGAGTGACCTCATCCTCC-3P)
which contains the PAI-2 CRE [10] (bottom panel). Extracts were
incubated with antibodies speci¢c to ATF-1, ATF-2, CREB,
CREM, c-fos, c-jun or jun-D as indicated (+). Migration pro¢les
were then compared on 5% native polyacrylamide gels as described
in Section 2.
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2.7. Preparation of nuclear proteins
The preparation of nuclear proteins from HT-1080 cells was per-
formed as previously described [9].
3. Results
3.1. Identi¢cation of tPACRE and PAI-2 CRE binding proteins
in HT-1080 cells
A major tPACRE binding protein identi¢ed in HT-1080 cell
nuclei has previously been found to be CREB (CRE binding
protein). We used an extensive range of antibodies in super-
shift experiments to identify additional HT-1080 nuclear fac-
tors associated with the tPACRE and the PAI-2 CRE sites
under basal conditions. Antibodies speci¢c for ATF-1, ATF-
2, CREB-1, CREM, c-fos, c-jun or jun-D were used for this
purpose. As shown in Fig. 1, the predominant tPACRE bind-
ing protein in HT-1080 cells was c-jun. CREB was also clearly
part of the assembly of tPACRE binding proteins (as previ-
ously described). Anti-ATF-2 antibodies produced a weak
(and inconsistent) supershifted complex, while antibodies
against ATF-1 and c-fos failed to generate supershifted com-
plexes. jun-D- and CREM-speci¢c complexes became appar-
ent only after longer exposure of the gel to X-ray ¢lm.
An identical experiment performed using the PAI-2 CRE
oligomer as a probe indicated that the most predominant
PAI-2 CRE binding protein in the same extracts was also c-
jun, with clear supershifted complexes attributed to CREB
and ATF-2, and a weaker shift attributed to jun-D.
CREB-mediated transactivation of promoters has been
shown to be dependent on the phosphorylation status of
Ser119 [11,17]. We performed experiments to determine
whether there was any di¡erence in the degree of Ser119-phos-
phorylated CREB bound to either the tPACRE or the PAI-2
CRE and also whether this could be in£uenced by PMA treat-
ment. To this end, nuclear proteins were extracted from cells
treated with PMA for 1, 6 and 24 h and assessed for Ser119-
phosphorylated CREB by EMSA supershift experiments us-
ing an antibody that speci¢cally recognised the Ser119-phos-
phorylated form of CREB (anti-p-CREB). As shown in Fig.
2, CREB associating with both the tPACRE and the PAI-2
CRE was constitutively phosphorylated on Ser119. Further-
more, the results clearly show that the degree of phosphory-
lated CREB was substantially stronger while bound to the
tPACRE than the PAI-2 CRE. PMA treatment reduced the
degree of Ser119-phosphorylated CREB bound to the tPA-
CRE. PMA treatment also appeared to slightly reduce the
levels of Ser119-phosphorylated CREB bound to the PAI-2
CRE.
To determine whether PMA treatment resulted in a more
pronounced change in the Ser119 phosphorylation status of
total CREB within the nuclear compartment, we performed
Western blot experiments using nuclear extracts prepared
from HT-1080 cells following a PMA time course. Unfortu-
nately, the p-CREB antibody was not suited to this approach
and the results were inconclusive (data not shown). Nonethe-
less, the most important parameter in this context is the de-
gree of Ser119 phosphorylation of CRE-bound CREB, which
we have attempted to demonstrate in this study.
Taken together, results of these supershift experiments in-
dicate that there are a number of common nuclear proteins
that associate with the tPACRE and PAI-2 CRE sites, the
most obvious being c-jun and CREB. The relative abundance
of c-jun bound to both CRE sites is suggestive of a role for
this transcription factor in the regulation of t-PA and PAI-2
expression. However, since there was a marked di¡erence be-
tween the relative levels of Ser119-phosphorylated CREB con-
stitutively bound to these sites, we focused our attention on
the role of Ser119-phosphorylated CREB in the di¡erential
control of the t-PA and PAI-2 gene expression. Furthermore,
the phosphorylation status of Ser119 is well known to modu-
late the ability of CREB to transactivate gene promoters
[11,17].
3.2. CREBala119 overexpressed in HT-1080 cells binds to the
t-PA and PAI-2 CRE sites and selectively disrupts PAI-2
gene expression
To address the role of Ser119-phosphorylated CREB in the
control of t-PA and PAI-2 gene expression we generated a
plasmid expressing a dominant negative CREB (pCI-
CREBala119) that could not be phosphorylated at Ser119.
HT-1080 cells were transfected with pCI-CREBala119 and
G418 resistant clones (about 200) were pooled. In this series
of experiments, pooled populations of HT-1080 cells trans-
fected with wild-type CREB (CREBwt) and the empty pCI-
Fig. 2. Time-dependent changes in the Ser119 phosphorylation sta-
tus of tPACRE and PAI-2 CRE bound CREB following PMA
treatment. Supershift experiments were performed to assess changes
in the degree of Ser119-phosphorylated CREB bound to the tPA-
CRE and PAI-2 CRE sites following PMA treatment. Nuclear pro-
teins were harvested from HT-1080 cells treated with 25 nM PMA
for 0, 1, 6 or 24 h. A supershift experiment was performed using la-
belled tPACRE and PAI-2 CRE oligonucleotide probes and anti-
bodies speci¢c for CREB and the Ser119-phosphorylated form of
CREB (p-CREB) as described in the legend to Fig. 1. Migration
pro¢les were then compared on 5% native polyacrylamide gels.
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neo vector were also generated. Nuclear extracts prepared
from these pooled populations of transfected cells were as-
sessed for total CREB (phosphorylated and non-phosphory-
lated) and Ser119-phosphorylated CREB by supershift assays
using labeled oligomers harbouring the tPACRE and PAI-2
CRE as probes.
As shown in Fig. 3, the transfection of cells with either pCI-
CREBwt or pCI-CREBala119 resulted in a marked increase in
CREB binding to both the tPACRE and the PAI-2 CRE sites.
Interestingly, there was no concomitant increase in Ser119-
phosphorylated CREB binding to either the tPACRE or the
PAI-2 CRE sites in cells overexpressing CREBwt. This may
suggest that there is a limitation to the extent by which CREB
can be phosphorylated at this residue or that a phosphatase
exists to limit the degree of CREB phosphorylation.
Cells overexpressing CREBala119, although displaying abun-
dant CREB supershifts, still produced a supershifted complex
when using the anti-p-CREB antibody, but the intensity of
this complex was weaker compared to the supershift produced
in cells overexpressing CREBwt. The reason for the back-
ground Ser119-phosphorylated CREB activity in the pooled
population of cells expressing pCI-CREBala119 is most likely
due to di¡erences in the degree of CREBala119 expression with-
in the individual clones of the pooled population.
To assess the e¡ect of the overexpressed wild-type and mu-
tant CREB proteins on the expression of endogenous t-PA
and PAI-2 mRNA, the pooled populations of HT-1080 cells
stably transfected with pCI-neo, pCI-CREBwt and pCI-
CREBala119 were treated with for 4, 8 or 24 h with PMA.
Total RNA was extracted and levels of endogenous t-PA
and PAI-2 mRNA assessed by Northern blot analyses. As
shown in Fig. 4, constitutive levels of endogenous t-PA
mRNA were similar between the cell groups. PMA treatment,
however, still suppressed levels of t-PA mRNA in cells trans-
fected with the empty pCI-neo plasmid as well as in cells
overexpressing either CREBwt or CREBala119. In contrast,
PMA treatment did not result in an increase in PAI-2
mRNA levels in cells overexpressing CREBala119. This was
not a consequence of a generalised increase in CREB protein,
because PAI-2 mRNA levels in HT-1080 cells overexpressing
CREBwt were increased by PMA in a manner similar to that
seen in cells transfected with pCI-neo. To con¢rm the selec-
tivity of these observations, PMA treatment resulted in a sim-
ilar increase of collagenase mRNA in pCI-neo, pCI-CREBwt
and pCI-CREBala119 expressing cells. Taken together, these
data indicate that induction of PAI-2 mRNA by PMA is de-
pendent upon a functional CREB protein.
4. Discussion
The functional importance of the cAMP responsive element
binding sites in the t-PA and PAI-2 gene promoters is well
documented [5,10]. It is also clear that, despite the sequence
similarity between these elements, their relative contribution
to the regulation of t-PA and PAI-2 gene expression is quite
di¡erent. For the t-PA gene, mutagenesis of the CRE site in
the t-PA promoter, reduces basal expression by 50% and
weakens, but does not completely inhibit, PMA-mediated in-
Fig. 3. CREBala119 overexpressed in HT-1080 cells binds to the t-PA
and PAI-2 CRE sites. Nuclear extracts prepared from pooled popu-
lations of HT-1080 cells stably transfected with pCI-neo, pCI-
CREBwt or pCI-CREBala119 were incubated with labeled double-
stranded oligomers harbouring either the tPACRE (top panel) or
the PAI-2 CRE (bottom panel), followed by addition of antibodies
against CREB or p-CREB as described in Fig. 1. Migration pro¢les
were then compared on 5% native polyacrylamide gels. The position
of the complex supershifted by the anti-CREB antibodies is indi-
cated to the right of the ¢gure.
Fig. 4. PAI-2 gene expression is selectively disrupted in pooled pop-
ulations of HT-1080 cells overexpressing CREBala119. Pooled popula-
tions of HT-1080 cells stably transfected with either pCI-neo (wild-
type), pCI-CREBwt or pCI-CREBala119 were treated with 25 nM
PMA for various times up to 24 h. Total RNA was prepared and
electrophoresed through a 1% agarose gel containing 20% formalde-
hyde, then transferred to a Nylon membrane. The ¢lter was sequen-
tially hybridised with 32P-labeled cDNA inserts speci¢c for t-PA,
PAI-2, collagenase and L-actin. This experiment was performed on
at least three separate occasions with similar results being obtained
each time. Lanes 1^5: pCI-neo (wild-type) transfected cells; lanes 6^
11: pCI-CREBwt transfected cells ; lanes 11^15: pCI-CREBala119
transfected cells.
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duction in transfected HeLa cells [5] and in endothelial cells
[9].
For the PAI-2 promoter, the role of the CRE site is partic-
ularly important, as mutagenesis of this motif in the absence
of other promoter mutations completely abolishes both basal
activity and PMA-mediated induction in transfected HT-1080
cells [10]. The aim of this study was, ¢rstly, to identify and
compare the tPACRE and PAI-2 CRE binding proteins and,
secondly, to determine whether di¡erences in the binding of
these proteins contributed to the opposite regulation of these
two genes in HT-1080 cells.
In our previous reports, we described CREB as a major
tPACRE binding protein in HT-1080 cells. Here we show
that tPACRE-bound CREB is constitutively phosphorylated
on Ser119, although the percentage of phosphorylation can-
not be accurately determined. c-jun was shown to be the singly
most prominent tPACRE binding protein in these cells. Ex-
periments performed using the PAI-2 CRE oligomer as a
probe indicated that some of the HT-1080 cell-derived factors
that recognise the tPACRE also recognise the PAI-2 CRE,
namely c-jun and CREB. Our results also demonstrated that
the degree of Ser119-phosphorylated CREB bound to the
PAI-2 CRE was notably weaker than that seen for the tPA-
CRE. We therefore focused our attention towards determin-
ing whether the Ser119 residue of CREB in£uenced expression
of the t-PA and PAI-2 genes since the phosphorylation status
of the Ser119 residue is known to greatly in£uence the ability
of CREB to associate with co-factors and subsequently trans-
activate gene promoters [11,17^20]. Furthermore, the role of
this residue on gene expression can also be cell-type speci¢c.
For example phosphorylation of the Ser119 counterpart in rat
CREB (Ser133) was shown to inhibit hepatic cell proliferation
[21], whereas expression of a mutant CREB that could not be
phosphorylated on Ser119 results in defective thymocyte pro-
liferation in transgenic mice [22]. Interestingly, circumstantial
data suggests that CREB may regulate t-PA expression in
vivo. CREB is strongly expressed in the brain [23,24] and is
implicated in the trans-activation of immediate early genes
involved in late phase long-term potentiation (L-LTP), since
transgenic mice over-expressing a dominant negative mutant
form of CREB have impaired L-LTP [25,26]. Interestingly,
like CREB 3/3 mice, t-PA 3/3 mice also display impaired
in L-LTP [23,27].
We speculated that di¡erences in the degree of the Ser119
phosphorylation status of CREB might in£uence constitutive
expression directed by the t-PA and PAI-2 gene promoters
and/or their abilities to respond to certain agonists. To ad-
dress this possibility, we constructed a dominant negative
CREB protein, CREBala119 and overexpressed this protein in
HT-1080 cells. Constitutive and PMA-modulated expression
of the endogenous t-PA and PAI-2 genes in both individual
clones (data not shown) and in pooled populations of HT-
1080 cells expressing the mutant CREB protein was assessed
by Northern blotting. Results indicated that PMA-mediated
suppression of t-PA mRNA was essentially unaltered in cells
expressing CREBala119, whereas PMA-mediated induction of
PAI-2 mRNA was greatly impaired. Furthermore, the fact
that overexpression of CREBwt in pooled populations of cells
did not in£uence the PMA-modulated response of either gene
highlights the selective e¡ect of the dominant negative form of
CREB. Taken together, these ¢ndings demonstrate that the
Ser119 residue of CREB is critical for the regulation of the
PAI-2 gene. The fact that PMA treatment resulted in only a
minor change in the degree of Ser119 phosphorylation raises
the possibility that the marked disruption of the PAI-2 gene
due to the expression of the CREB mutant may not be related
to the inability of CREB to be phosphorylated at position
119, and may indicate a di¡erent role for Ser119 in the
CREB protein. The mechanism by which CREB conveys its
in£uence on the PAI-2 gene in HT-1080 cells is presently un-
known. The kinase inducible domain of the CREB protein
harbours many phosphoacceptor sites that are subject to
phosphorylation by various kinases including PKA, PKC
and CK II [18,28,29] the most important being Ser119 as we
have focused on in this study. Phosphorylation of this residue
permits CREB to associate with the CREB-binding protein
(CBP) which in turn can acetylate histones and initiate relax-
ation of DNA to allow other essential transcription factors to
engage and activate transcription [30]. Also, the phosphoryla-
tion of Ser119 can also create new phosphorylation sites for
other kinases that in turn can in£uence the transactivation
potential of CREB [31]. Whether these events, or a Ser119-
phosphorylation-independent process, occurs during PMA-
mediated induction of the PAI-2 gene remains to be deter-
mined.
We were surprised to observe that overexpression of the
CREB mutant protein did not in£uence t-PA mRNA expres-
sion since the degree of Ser119-phosphorylated CREB bound
to the tPACRE was greater than that seen for the PAI-2 CRE
and the fact that PMA treatment signi¢cantly reduced the
levels of Ser119-phosphorylated CREB bound to the tPA-
CRE. The lack of an e¡ect of CREBala119 on PMA-mediated
suppression of t-PA mRNA in HT-1080 cells presents a num-
ber of other possibilities. Indeed, this study has not com-
pletely excluded a role for CREB in the control of the t-PA
gene in HT-1080 cells as other phosphorylation sites on the
CREB protein may be required to convey PMA-mediated
downregulation of the t-PA gene in HT-1080 cells. In this
context, it would be interesting to determine whether an in-
active CREB, for example one that possesses a mutation in
either the DNA binding or transactivation domain, would
interfere with the regulation of the t-PA gene in these cells.
Quite apart from CREB itself, other tPACRE binding pro-
teins in HT-1080 cells need to be considered. c-jun is an in-
teresting candidate as a possible regulatory molecule for t-PA
and possibly for PAI-2 gene regulation, as it is an abundant
tPACRE and PAI-2 CRE binding factor. It is also reasonable
to consider the roles of other regulatory sites within the t-PA
promoter. The Sp1 site located approximately 165 bp down-
stream from the tPACRE may be relevant as it has been
shown to cooperate with the tPACRE in the maintenance of
basal expression in HT-1080, HeLa and human endothelial
cells [5,8]. Clearly, much work is needed to understand the
basis of PMA-mediated suppression of t-PA in HT-1080 cells
and the role of CREB and the other tPACRE binding pro-
teins in this process.
In summary, this study is the ¢rst to demonstrate an im-
portant role for CREB in the induction of the PAI-2 gene in
HT-1080 cells. This e¡ect is dependent on the presence of
Ser119 in the CREB protein. We also show that PMA-medi-
ated suppression of the t-PA gene in HT-1080 cells does not
require Ser119-phosphorylated CREB, suggesting that the
suppression of the t-PA gene under these conditions requires
a di¡erent process.
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